U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT06974110) titled 'Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors' on May 02.
Brief Summary: This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341 administered orally as a single agent or combination therapy in patients with microsatellite instability high (MSI-H) or DNA mismatch repair deficiency (dMMR) solid tumors.
Study Start Date: June, 2025
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumor
Metastatic Solid Tumor
Endome...